-
FUS–PARP1 Phase Separation and PAR Structure
2026-08-28
The 2024 study by Sukhanova and colleagues shows that FUS microphase separation with PARylated PARP1 depends not only on protein abundance, but also on polyamines, divalent cations, and PAR branching. Its comparative biochemical design provides a framework for interpreting how PARP1-generated condensates may organize DNA damage response processes, while also defining important limits for translating in vitro phase behavior to cancer models.
-
Omeprazole (A2845): H+,K+-ATPase Protocol
2026-08-28
Omeprazole (SKU A2845) provides a dossier-defined H+,K+-ATPase inhibitor for controlled gastric acid secretion research, including stimulation-based acid formation assays and antiulcer activity study design. Its limited water and ethanol solubility requires DMSO-based handling and fresh solution preparation; it is for scientific research only and not for diagnostic, therapeutic, or medical use.
-
Reserpine N1867: Practical Lab Workflow Guide
2026-08-27
Reserpine (SKU N1867) provides a defined, high-purity research compound for controlled neurotransmitter depletion research, antihypertensive mechanism studies, and neuropharmacology research. This guide addresses preparation, storage, identity checks, and troubleshooting while defining the material as research-use-only and not suitable for diagnostic, clinical, or veterinary applications.
-
Gastric Cancer Assembloids Model Tumor–Stroma Responses
2026-08-27
This 2025 study develops patient-derived gastric cancer assembloids by combining matched tumor organoids with tumor-derived stromal subpopulations. The model shows that stromal composition reshapes gene expression and drug sensitivity, creating a more physiologically relevant framework for studying treatment resistance and personalized drug screening.
-
Calnexin Shapes CFTR Variant Rescue
2026-08-26
Tedman et al. used deep mutational scanning to examine how the chaperone calnexin influences expression and corrector responsiveness across 232 clinical CFTR variants. The study shows that calnexin is a variant-dependent determinant of CFTR surface expression and pharmacological rescue, providing a framework for interpreting why correctors such as VX-661 perform differently across cystic fibrosis genotypes.
-
ATRX Loss Sensitizes High-Grade Glioma to RTK Inhibitors
2026-08-26
The 2022 Cancers study identified a genotype-associated vulnerability in high-grade glioma: ATRX-deficient cells were more sensitive to multi-targeted receptor tyrosine kinase and PDGFR inhibitors than comparator cells. The findings also indicate that combining selected RTK inhibitors with temozolomide may produce greater cellular toxicity, supporting ATRX status as a variable for interpreting targeted-therapy studies.
-
Stiripentol: LDH Inhibition in Epilepsy Research
2026-08-25
Stiripentol is a noncompetitive LDH inhibitor that targets human LDH1 and LDH5 for mechanistic studies of lactate flux and epileptiform activity. Its direct LDH action should be distinguished from MPC-driven lactate biology and histone lactylation reported in colorectal cancer models.
-
Intravesical p21 mRNA-LNP Therapy for Bladder Cancer
2026-08-25
The reference study develops a localized, nonviral strategy for bladder cancer by delivering chemically modified p21 mRNA in lipid nanoparticles through intravesical administration. Its preclinical findings connect restored nuclear p21 expression with cell-cycle inhibition, DNA-damage signaling, apoptosis, tumor suppression, and limited systemic exposure.
-
Halazone and Sodium Current Inactivation in Frog Fibers
2026-08-24
A 1986 voltage-clamp study used Halazone and several chemically selective reagents to test whether methionine, sulfhydryl, histidine, tyrosine, or arginine residues control sodium-current inactivation in frog myelinated nerve fibers. Halazone and hypochlorous acid strongly disrupted inactivation, while the comparative reagent pattern argued against a uniquely methionine-centered mechanism and supported a tentative role for chemically modifiable membrane components, including lipids.
-
AZD3463: ALK/IGF1R Inhibitor Research Guide
2026-08-24
AZD3463 is an orally bioavailable ALK/IGF1R inhibitor for preclinical ALK-driven cancer research. The product dossier describes activity against wild-type and mutant ALK, PI3K/AKT/mTOR pathway suppression, enhanced chemotherapy response, and tumor-growth reduction in orthotopic neuroblastoma xenografts.
-
Captopril Beyond ACE: A Translational Research Playbook
2026-08-23
Captopril is more than a benchmark ACE inhibitor for hypertension research. By connecting ACE inhibition with bradykinin B2 receptor biology, this article outlines a translational workflow for studying vascular, gastrointestinal, and preclinical cancer phenotypes while distinguishing established evidence from testable hypotheses.
-
Stiripentol, LDH, and Lactate Flux in Epilepsy
2026-08-22
Explore how Stiripentol, a noncompetitive LDH inhibitor, can be used to interrogate lactate flux, astrocyte-neuron lactate shuttle modulation, and seizure biology. This article translates recent histone lactylation findings into practical assay decisions while distinguishing established evidence from testable research hypotheses.
-
NIID Patient iPSC Model with NOTCH2NLC Expansion
2026-08-21
This resource study establishes HZSMHCi002-A, a patient-derived induced pluripotent stem cell line carrying a GGC repeat expansion in the 5′ untranslated region of NOTCH2NLC, a major genetic cause of neuronal intranuclear inclusion disease. The line provides a characterized starting point for modeling NIID cellular pathology and testing future interventions, while its single-donor design and lack of gene correction define important limits for interpretation.
-
Nintedanib: ATRX-Stratified Research Design
2026-08-20
Nintedanib (BIBF 1120) is a triple angiokinase inhibitor suited to mechanism-driven angiogenesis and tumor studies. This article develops an ATRX-stratified assay framework that connects receptor tyrosine kinase biology with practical decisions about controls, endpoints, exposure, and translational limits.
-
SGI-1027: A DNMT Inhibitor for Smarter Cancer Assays
2026-08-20
SGI-1027 is a DNA methyltransferase inhibitor that connects DNMT biochemistry with more rigorous cancer-cell response assays. This guide explains how to distinguish growth inhibition from cell killing when evaluating DNA methylation inhibition and tumor suppressor gene reactivation.